OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

OKYO enrolls first patients in Phase 3 NEPTUNE trial for neuropathic corneal pain.

What the company is saying

OKYO Pharma Limited is announcing the initiation and first patient enrollment in its Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP). The company frames urcosimod as a potential first-in-class, disease-modifying treatment for a condition with no FDA-approved therapies. The release highlights the involvement of Dr. Melissa Toyos, who enrolled the first patients at Toyos Clinic in Nashville, and includes commentary from Dr. Flavio Mantelli, Chief Medical Officer, emphasizing the milestone nature of this trial start. The company stresses the significant unmet medical need in NCP and positions the trial as a critical step toward regulatory approval. The announcement details the trial's multicenter, registrational design, its alignment with FDA guidance, and the inclusion of sites across the United States and Europe. The language is optimistic and forward-looking, but does not present interim results or financial data.

What the data suggests

The disclosed facts confirm that the NEPTUNE Phase 3 trial for urcosimod has begun enrolling patients, with the first site activated at Toyos Clinic in Nashville, Tennessee. The study will enroll patients at multiple sites in the United States, Italy, Spain, and France, with a dosing regimen of 4 drops per day for 12 weeks. The primary efficacy endpoint is the change in ocular pain from baseline to end of treatment, measured by Visual Analog Scale (VAS) score, with secondary endpoints including Quality-of-Life scores and in-vivo confocal microscopy findings. The trial is registered as NCT07838506 and is designed as a registrational study in line with FDA guidance. No interim efficacy, safety data, or financial figures are disclosed. The announcement provides operational detail on trial design and scope but does not supply evidence for urcosimod's efficacy or safety in humans, nor does it quantify the size of the trial or expected timelines for completion.

Analysis

The announcement is positive in tone, highlighting the enrollment of the first patients in a Phase 3 trial, which is a meaningful operational milestone for a clinical-stage biotech. However, the majority of the claims about urcosimod's potential as a 'first-in-class' or 'disease-modifying' treatment are forward-looking and not yet substantiated by clinical data. The only realised progress is the initiation of the trial and first patient enrollment; no interim efficacy or safety results are disclosed. The benefits of the trial, if successful, are long-term, as Phase 3 studies typically take years to complete and regulatory approval would follow only after positive results. There is no mention of large capital outlay or immediate financial impact, and no financial or profitability metrics are disclosed, which is normal for a pre-revenue biotech but limits the signal to weak_positive. The language around 'significant unmet medical need' and 'potential first-in-class' inflates the narrative relative to the actual progress, which is limited to trial initiation.

Risk flags

• ●The main operational risk is the lengthy and uncertain timeline inherent in Phase 3 clinical trials, which can be delayed by slow enrollment, protocol amendments, or unforeseen safety issues. This matters because extended timelines increase costs and can erode investor confidence if milestones are missed.
• ●There is significant execution risk, as the trial must demonstrate both safety and efficacy to support regulatory approval, and no interim results or patient numbers are disclosed to gauge early progress. The absence of such data means investors cannot assess the likelihood of success or the pace of enrollment.
• ●The company provides no financial disclosure or update on funding status, which is relevant because Phase 3 trials are capital-intensive and pre-revenue biotechs often face funding gaps that can lead to dilution or program delays.
• ●The claims about urcosimod's 'first-in-class' status and dual mechanism are not substantiated by published clinical data in this announcement, raising the risk that expectations may outpace actual results if future data do not support these assertions.

Bottom line

OKYO Pharma has initiated patient enrollment in its Phase 3 NEPTUNE trial for urcosimod in neuropathic corneal pain, marking a key operational milestone but providing no efficacy, safety, or financial data. The trial's multicenter, FDA-guided design and international scope are positives, but the absence of interim results or enrollment figures means investors have no visibility on trial progress or likelihood of success. The company's narrative is aspirational, emphasizing unmet need and first-in-class potential, but these claims remain unproven until clinical data are released. Investors should recognize that value realization is likely years away and that funding needs may arise before trial completion. The most important takeaway is that this is an early-stage signal of progress, not a validation of urcosimod's efficacy or commercial potential.

Announcement summary

(NASDAQ:OKYO) OKYO Pharma Limited announced the enrollment of the first patients in its Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP). The first patients were enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN. The NEPTUNE trial is a multicenter, registrational Phase 3 study designed in accordance with U.S. Food and Drug Administration (FDA) guidance. The trial is being conducted at multiple clinical sites across the United States and Europe, including Italy, Spain, and France. Patients in the study will receive 4 drops of urcosimod per day for 12 weeks. The primary efficacy endpoint is the change from baseline to end of treatment in ocular pain as assessed by the Visual Analog Scale (VAS) score. Additional efficacy endpoints include Quality-of-Life scores and in-vivo confocal microscopy (IVCM) findings. The NEPTUNE trial is registered as NCT07838506 on clinicaltrials.gov. Urcosimod is described as a first-in-class, lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein-coupled-receptor, which is found on immune cells of the eye and on neurons and glial cells in the dorsal root ganglion. Urcosimod has demonstrated ocular analgesic and anti-inflammatory pharmacologic activity through its dual mechanism of action. Neuropathic corneal pain is characterized as a chronic, severe, and debilitating condition with no FDA-approved treatment options, representing a significant unmet medical need. Dr. Melissa Toyos stated that neuropathic corneal pain is one of the most debilitating conditions seen in practice and that there are currently no FDA-approved therapies for these patients. Dr. Flavio Mantelli, Chief Medical Officer of OKYO Pharma, commented that the activation of the first site and initiation of the NEPTUNE trial is an important milestone for building clinical evidence to support a potential first disease-modifying treatment for NCP. OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases, with ordinary shares listed on the Nasdaq Capital Market.

Disagree with this article?